your market intelligence analyst
Search Results
121 results
Your search is now limited to «Bladder Cancer» expert search.
PR Newswire 09/18/2019 08:00
Muscle-invasive bladder cancer (MIBC), an aggressive and potentially lethal form of the disease, affects between 20 and 25 percent of patients diagnosed each year.
More from PR Newswire:
pharmaphorum 09/17/2019 04:36
The US regulator is considering use of the Nectin-4-targeting ADC as treatment for advanced urothelial carcinoma (UC) – the most common form of bladder cancer – after the failure of chemotherapy and cancer immunotherapy.
More from pharmaphorum:
ENDPOINTS 09/16/2019 10:15
Seattle Genetics has secured a speedy review of its second armed antibody, courtsey the FDA. The company’s ‘breakthrough’ Astellas-partnered drug — enfortumab vedotin — has procured from the US regulator, after data showed it helped patients with stubborn type urothelial cancer. The drug-induced a (ORR) in 128 patients whose disease had progressed despite treatment with both platinum-containing chemotherapy and a checkpoint inhibitor in the one-arm EV-201 study.
More from ENDPOINTS:
GADD45a Mediated Cell Cycle Inhibition Is Regulated By P53 In Bladder Cancer Na Han,1,2,* Fang Yuan,2,3,* Peng Xian,2,3,* Nan Liu,2,3 Jianmin Liu,4 Haiyan Zhang,1,2 Huayong Zhang,5 Kai Yao,6 Gangjun Yuan2,3 1Health Examination and Oncology Screening Center, Chongqing University Cancer Hospital, Chongqing 400030, People’s Republic of China; 2Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400030, People’s Republic of China; 3Department of Urology, Chongqing University Cancer Hospital, Chongqing 400030, People’s Republic of China; 4Department of Otolaryngology Head and Neck Surgery, People’s Hospital of Deyang, Deyang 618000, People’s Republ.
More from International Journal of COPD: 09/13/2019 07:05
Patients enrolled in VESPER study Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort Combination Product: neoadjuvant chemotherapy with cisplatine Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine.
More from 09/12/2019 16:21
The Center of Excellence for Bladder Cancer is focused on bringing multi-disciplinary, cutting-edge, and highly personalized care to patients with all forms of bladder cancer.
More from
PubMed News (NIH) 09/06/2019
Our previous studies found that hundreds of circRNAs were aberrantly expressed in bladder cancer (BC) by high-throughput sequencing and we have confirmed that the downregulated circRNAs circHIPK3, BCRC3 and circNR3C1 played inhibitory roles in BC progression.
More from PubMed News (NIH):
Onclive 09/04/2019 13:29
Petros Grivas, MD, PhD Immunotherapy has completely transformed bladder cancer treatment, said Petros Grivas, MD, PhD, and a plethora of ongoing clinical trials evaluating this class of drugs in combination with chemotherapy, other checkpoint inhibitors, and targeted agents, could lead to more options.
More from Onclive:
Absolute scores based on the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) dietary recommendations were not associated with prostate or bladder cancer risk.
More from Cancer Epidemiology, Biomarkers & Prevention Recent Issues (abstracts):
Advanced bladder cancer is associated with a poor prognosis and limited treatment options. The PI3K/AKT/mTOR pathway is frequently activated in this disease and can be a potential therapeutic target for treatment intervention. We studied the antitumor efficacy of a new targeted therapy, TAK-228 (oral mTORC1/2 inhibitor), in preclinical models of bladder cancer. We evaluated the effects of TAK-228 in combination with a PI3Kα inhibitor (TAK-117) or with chemotherapy (paclitaxel). We used six bladder cancer cell lines and in vivo xenografts models. TAK-228 strongly inhibited cell proliferation in vitro , and reduced tumor growth and angiogenesis in vivo . Three possible biomarkers of response to TAK-228 (basal levels of 4E-BP1, p-4E-BP1/4E-BP1.
ETHealthWorld (India) 08/25/2019 02:10
Smoking is a well-established risk factor for bladder cancer, but findings on the relationship between duration of smoking cessation and the reduction in bladder cancer risk are inconsistent," said Yueyao Li, the study's author.
More from ETHealthWorld (India):

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications